4-bromo-2-(methylthio)thiophene | 87310-65-4

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 4-bromo-2-(methylthio)thiophene
• 英文别名: 4-bromo-2-methylsulfanyl-thiophene；4-bromo-2-methylthiothiophene；4-Brom-2-methylmercapto-thiophen；4-bromo-2-methylsulfanylthiophene
• CAS: 87310-65-4
• 化学式: C₅H₅BrS₂
• 分子量: 209.131
• InChiKey: RYZWFWQJUITPAQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  53.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-bromo-2-(methylthio)thiophene 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 生成 Methyl-<4-brom-thienyl-(2)>-sulfon
  参考文献：
  名称：

  [EN] SELECTIVE ESTROGEN REPECTOR MODULATOR FOR THE TREATMENT OF OSTEOARTHRITIS
  [FR] MODULATEUR SÉLECTIF DES RÉCEPTEURS D'OESTROGÈNES

  摘要：

  公开号：

  WO2010036497A3
• 作为产物：
  描述：

  2,4-二溴噻吩 、 二甲基二硫 在 正丁基锂 、 水 、 氯化铵 作用下， 以 hexanes 、 乙醚 为溶剂， 生成 4-bromo-2-(methylthio)thiophene
  参考文献：
  名称：

  [EN] SELECTIVE ESTROGEN REPECTOR MODULATOR FOR THE TREATMENT OF OSTEOARTHRITIS
  [FR] MODULATEUR SÉLECTIF DES RÉCEPTEURS D'OESTROGÈNES

  摘要：

  公开号：

  WO2010036497A3

文献信息

• Ether derivatives having 5-lipoxygenase inhibitory activity
  申请人：Zeneca Limited

  公开号：US05478842A1

  公开（公告）日：1995-12-26

  The invention concerns ether derivatives of the formula I Q.sup.1 --X--Ar--Q.sup.2 I wherein Q.sup.1 is an optionally substituted 9-, 10- or 11-membered bicyclic heterocyclic moiety containing one or two nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur; X is oxy, thio, sulphinyl or sulphonyl; Ar is optionally substituted phenylene, pyridinediyl, pyrimidinediyl, thiophenediyl, furandiyl, thiazolediyl, oxazoiediyl, thiadiazoiediyl or oxadiazolediyl; and Q.sup.2 is selected from the groups of the formulae II and III: ##STR1## wherein R.sup.1 is hydrogen, (2-5C)alkanoyl or optionally substituted benzoyl; R.sup.2 is (1-4C)alkyl; and R.sup.3 is hydrogen or (1-4C)alkyl; or R.sup.2 and R.sup.3 are linked to form a methylene, vinylene, ethylene or trimethylene group; or a pharmaceutically-acceptable salt thereof; processes for their preparation; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors.

  本发明涉及公式I的醚衍生物 Q.sup.1 --X--Ar--Q.sup.2 I，其中Q.sup.1是可选地取代的含有一个或两个氮杂原子的9-、10-或11-成环杂环部分，并且可选地含有从氮、氧和硫中选择的另外一种杂原子；X是氧乙基、硫乙基、亚磺酰基或磺酰基；Ar是可选地取代的苯基、吡啶基、嘧啶基、噻吩基、呋喃基、噻唑基、恶唑基、噻二唑基或恶二唑基；Q.sup.2是公式II和III的组中选择的：##STR1##，其中R.sup.1是氢、(2-5C)烷酰或可选地取代的苯甲酰；R.sup.2是(1-4C)烷基；R.sup.3是氢或(1-4C)烷基；或者R.sup.2和R.sup.3连接形成一个亚甲基、乙烯基、亚乙基或三亚甲基组；或其药物可接受的盐；其制备过程；包含它们的药物组合物以及它们作为5-脂氧合酶抑制剂的使用。
• Pyrrolidine derivatives
  申请人：Zeneca Limited

  公开号：US05420298A1

  公开（公告）日：1995-05-30

  The invention concerns pyrrolidine derivatives of the formula ##STR1## wherein Ar.sup.1 is optionally-substituted phenyl, naphthyl or a 10-membered bicyclic heterocyclic moiety containing one or two nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur; A is a direct link to the group X or A is (1-4C)alkylene; X is oxy, thio, sulphinyl or sulphonyl; Ar.sup.2 is phenylene, pyridinediyl, pyrimidinediyl, thiophendiyl, furandiyl or thiazolediyl; R.sup.1 is (1-4C)alkyl, (3-4C)alkenyl or (3-4C)alkynyl; R.sup.2 is (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, halogeno-(1-4C)alkyl, halogeno-(2-4C)alkenyl, halogeno-(2-4C)alkynyl, (1-4C)alkoxy-(2-4C)alkyl, hydroxy-(2-4C)alkyl, cyano-(1-4C)alkyl, carboxy-(1-4C)alkyl, carbamoyl-(1-4C)alkyl, (1-4C)alkoxycarbonyl-(1-4C)alkyl, N-(1-4C)alkylcarbamoyl-(1-4C)alkyl or N,N-di-(1-4C)alkylcarbamoyl-(1-4C)alkyl; and n is 1 or 2 and each R.sup.3 is independently hydrogen, hydroxy, (1-4C)alkyl or (1-4C)alkoxy; or a pharmaceutically-acceptable salt thereof; processes for their manufacture; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors.

  该发明涉及以下结构的吡咯烷衍生物：其中Ar.sup.1是可选择取代的苯基、萘基或含有一个或两个氮杂原子的10元杂环基团，且可选择地含有来自氮、氧和硫的进一步杂原子；A是直接连接到基团X的链或A是(1-4C)烷基链；X是氧、硫、亚硫酰基或磺酰基；Ar.sup.2是苯基、吡啶二基、嘧啶二基、噻吩二基、呋喃二基或噻唑二基；R.sup.1是(1-4C)烷基、(3-4C)烯基或(3-4C)炔基；R.sup.2是(1-4C)烷基、(2-4C)烯基、(2-4C)炔基、卤代-(1-4C)烷基、卤代-(2-4C)烯基、卤代-(2-4C)炔基、(1-4C)烷氧基-(2-4C)烷基、羟基-(2-4C)烷基、氰基-(1-4C)烷基、羧基-(1-4C)烷基、氨基甲酰基-(1-4C)烷基、(1-4C)烷氧羰基-(1-4C)烷基、N-(1-4C)烷基氨基甲酰基-(1-4C)烷基或N,N-二-(1-4C)烷基氨基甲酰基-(1-4C)烷基；n为1或2，每个R.sup.3独立地是氢、羟基、(1-4C)烷基或(1-4C)烷氧基；或其药学上可接受的盐；其制备方法；含有它们的药物组合物以及它们作为5-脂氧合酶抑制剂的用途。
• Oxime derivatives
  申请人：Zeneca Limited

  公开号：US05332757A1

  公开（公告）日：1994-07-26

  The invention concerns oxime derivatives of the formula I ##STR1## wherein R.sup.4 includes hydrogen, carboxy, carbamoyl, amino, cyano, trifluoromethyl, (1-4C)alkylamino, di-(1-4C)alkylamino and (1-4C)alkyl; R.sup.5 includes hydrogen, (1-4C)alkyl, (3-4C)alkenyl, (3-4C)alkynyl, (2-5C)alkanoyl, halogeno-(2-4C)alkyl and hydroxy-(2-4C)alkyl; Ar.sup.1 is phenylene or a heteroaryl diradical; A.sup.1 is a direct link to X.sup.1, or A.sup.1 is (1-4C)alkylene; X.sup.1 is oxy, thio, sulphinyl or sulphonyl; Ar.sup.2 is phenylene or a heteroaryl diradical; R.sup.1 is (1-4C)alkyl, (3-4C)alkenyl or (3-4C)alkynyl; and R.sup.2 and R.sup.3 together form a group of the formula -A.sup.2 -X.sup.2 -A.sup.3 - which together with the carbon atom to which A.sup.2 and A.sup.3 are attached define a ring having 5 or 6 ring atoms, wherein each of A.sup.2 and A.sup.3 is (1-3C)alkylene and X.sup.2 is oxy, thio, sulphinyl, sulphonyl or imino; or a pharmaceutically-acceptable salt thereof; processes for their manufacture; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors.

  该发明涉及公式I的肟衍生物 其中R.sup.4包括氢、羧基、氨基甲酰基、氨基、氰基、三氟甲基、(1-4C)烷基氨基、二-(1-4C)烷基氨基和(1-4C)烷基；R.sup.5包括氢、(1-4C)烷基、(3-4C)烯基、(3-4C)炔基、(2-5C)烷酰基、卤代-(2-4C)烷基和羟基-(2-4C)烷基；Ar.sup.1是苯基或杂环双基；A.sup.1是直接连接到X.sup.1的连接，或者A.sup.1是(1-4C)烷基；X.sup.1是氧、硫、亚砜基或砜基；Ar.sup.2是苯基或杂环双基；R.sup.1是(1-4C)烷基、(3-4C)烯基或(3-4C)炔基；R.sup.2和R.sup.3一起形成一个具有5或6个环原子的环的基团，其中A.sup.2和A.sup.3中的每一个是(1-3C)烷基，X.sup.2是氧、硫、亚砜基、砜基或亚胺；或其药学上可接受的盐；其制备方法；含有它们的药物组合物以及它们作为5-脂氧合酶抑制剂的用途。
• Acetanilide derivatives
  申请人：ZENECA LIMITED

  公开号：EP0610032A1

  公开（公告）日：1994-08-10

  The invention concerns acetanilide derivatives of the formula I wherein R⁴ is (1-4C)alkyl; R⁵ is hydrogen or (1-4C)alkyl; Ar¹ is phenylene, pyridinediyl or pyrimidinediyl; A¹ is a direct link to X¹ or A¹ is (1-4C)alkylene; X¹ is oxy, thio, sulphinyl or sulphonyl; Ar² is thiophenediyl, furandiyl, thiazolediyl, oxazolediyl, thiadiazolediyl or oxadiazolediyl; R¹ and R² together form a group of the formula -A²-X²-A³- which together with the oxygen atom to which A² is attached and with the carbon atom to which A³ is attached define a ring having 5 or 6 ring atoms, wherein each of A² and A³ is (1-3C)alkylene and X² is oxy, thio, sulphinyl or sulphonyl and which ring may bear one, two or three (1-4C)alkyl substituents; and R³ is (1-4C)alkyl; or pharmaceutically-acceptable salts thereof; processes for their manufacture; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors.

  该发明涉及具有以下式I的乙酰苯胺衍生物，其中R⁴是(1-4C)烷基；R⁵是氢或(1-4C)烷基；Ar¹是苯基、吡啶二基或嘧啶二基；A¹是直接连接到X¹的链或A¹是(1-4C)烷基；X¹是氧、硫、亚砜基或砜基；Ar²是噻吩二基、呋喃二基、噻唑二基、噁唑二基、噻二唑二基或噁二唑二基；R¹和R²一起形成一个具有5或6个环原子的环的基团，其中A²和A³各自是(1-3C)烷基，X²是氧、硫、亚砜基或砜基，该环可能具有一个、两个或三个(1-4C)烷基取代基；R³是(1-4C)烷基；或其药用可接受盐；其制备方法；含有它们的药物组合物以及它们作为5-脂氧合酶抑制剂的用途。
• Acylanilides having antiandrogenic activity
  申请人：Imperial Chemical Industries PLC

  公开号：US04535092A1

  公开（公告）日：1985-08-13

  Acylanilides of the formula ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are substituents defined in claim 1; wherein R.sup.4 is hydrogen or alkyl of up to 4 carbon atoms, or is joined to R.sup.5 as stated below; wherein R.sup.5 is hydrogen, hydroxy, or alkoxy or acyloxy each of up to 15 carbon atoms, or is joined to R.sup.4 to form an oxycarbonyl group such that together with the --N--CO--C-- part of the molecule it forms an oxazolidinedione group; wherein R.sup.6 is alkyl or halogenoalkyl of up to 4 carbon atoms; and wherein R.sup.7 is 5- or 6- membered saturated or unsaturated heterocyclic which contains one, two or three hetero atoms selected from oxygen, nitrogen and sulphur, which heterocyclic may be a single ring or may be fused to a benzo-ring, and which heterocyclic is unsubstituted or bears one or two substituents defined in claim 1; processes for their manufacture and pharmaceutical compositions containing them. The compounds possess antiandrogenic activity.

  公式为##STR1##的Acylanilides，其中R.sup.1、R.sup.2和R.sup.3为权利要求1中定义的取代基；其中R.sup.4为氢或最多4个碳原子的烷基，或与R.sup.5如下所述连接；其中R.sup.5为氢、羟基或最多15个碳原子的烷氧基或酰氧基，或与R.sup.4结合形成氧羰基基团，使其与分子中的--N--CO--C--部分一起形成氧氮杂环二酮基团；其中R.sup.6为最多4个碳原子的烷基或卤代烷基；其中R.sup.7为5-或6-成员饱和或不饱和杂环，其中包含从氧、氮和硫选出的一个、两个或三个杂原子，该杂环可以是单环或融合到苯环上，并且该杂环未取代或带有权利要求1中定义的一或两个取代基；制造它们的过程和含有它们的药物组成物。这些化合物具有抗雄激素活性。